Browne Jacobson advises US life sciences firm on international expansion deal

Browne Jacobson has supported a US-headquartered precision immunology company in signing a partnership agreement that expands its global presence.

The UK and Ireland law firm advised Scipher Medicine in its strategic alliance with Grupo Amarey, a market leader in the representation and distribution of technologies, solutions and services for the healthcare sector across Colombia, Panama and Costa Rica.

The collaboration marks Scipher Medicine’s first international expansion, enabling it to deliver personalised medicine solutions to patients with rheumatoid arthritis (RA) in Latin America, starting with Colombia.

Its innovative precision diagnostic, PrismRA, is the first molecular test of its kind that provides objective data to help healthcare professionals select the most effective biologic therapy for each RA patient, improving clinical outcomes while reducing unnecessary and ineffective treatments.

Browne Jacobson’s team was led by Clare Auty, Partner and Head of Independent Health and Social Care, and Viney Jhalley, Associate, who advised on commercial health aspects. Matthew Alderton, Partner, and Taylor Berzins, Associate, provided specialist data and regulatory input.

The team worked closely with Colombian law firm Cavelier Abogados, which provided advice from a Colombian legal perspective.

Clare said: “We are proud to have supported the in-house legal team at Scipher Medicine, following a referral by one of our US partner law firms, on this landmark deal that paves the way for it to deliver its innovative precision medicine technology to patients in Latin America.

“This is a great example of our firm’s ambitions to work with clients across the world that are working at the forefront of society’s biggest issues – with improving health outcomes at the very top of this agenda – as well as collaborate with other international law firms.

“We are excited about what the future holds for Scipher Medicine and its PrismRA diagnostic, which has enormous potential to advance precision medicine globally."

Reg Seeto, CEO of Scipher Medicine, said: “Our mission at Scipher Medicine is to eliminate the trial-and-error approach in the treatment of autoimmune diseases by providing physicians with actionable, data-driven insights. 

“Expanding into Latin America, starting with Colombia through our partnership with Grupo Amarey, is a key step in our global strategy. Grupo Amarey’s deep understanding of the local healthcare system and its commitment to innovation make them the ideal partner to bring PrismRA to the patients who can benefit most.”

With its extensive experience and strong presence in the healthcare market in Colombia, Grupo Amarey is in a privileged position to facilitate the adoption and integration of PrismRA into clinical practice.

Dr Manuel Camacho, General Manager of Grupo Amarey, added: “We are excited to partner with Scipher Medicine to introduce PrismRA in Colombia.

“Precision medicine holds tremendous potential to improve patient care, especially in complex diseases like rheumatoid arthritis. This collaboration reinforces our commitment to bringing cutting-edge diagnostic tools and new therapies to patients and healthcare professionals in Colombia, promoting more personalised and effective treatment decisions.”